» Articles » PMID: 29563797

Tumor-targeting Delivery of Herb-based Drugs with Cell-penetrating/tumor-targeting Peptide-modified Nanocarriers

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2018 Mar 23
PMID 29563797
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer has become one of the leading causes of mortality globally. The major challenges of conventional cancer therapy are the failure of most chemotherapeutic agents to accumulate selectively in tumor cells and their severe systemic side effects. In the past three decades, a number of drug delivery approaches have been discovered to overwhelm the obstacles. Among these, nanocarriers have gained much attention for their excellent and efficient drug delivery systems to improve specific tissue/organ/cell targeting. In order to enhance targeting efficiency further and reduce limitations of nanocarriers, nanoparticle surfaces are functionalized with different ligands. Several kinds of ligand-modified nanomedicines have been reported. Cell-penetrating peptides (CPPs) are promising ligands, attracting the attention of researchers due to their efficiency to transport bioactive molecules intracellularly. However, their lack of specificity and in vivo degradation led to the development of newer types of CPP. Currently, activable CPP and tumor-targeting peptide (TTP)-modified nanocarriers have shown dramatically superior cellular specific uptake, cytotoxicity, and tumor growth inhibition. In this review, we discuss recent advances in tumor-targeting strategies using CPPs and their limitations in tumor delivery systems. Special emphasis is given to activable CPPs and TTPs. Finally, we address the application of CPPs and/or TTPs in the delivery of plant-derived chemotherapeutic agents.

Citing Articles

Advances and prospects of precision nanomedicine in personalized tumor theranostics.

Mao Y, Xie J, Yang F, Luo Y, Du J, Xiang H Front Cell Dev Biol. 2024; 12:1514399.

PMID: 39712574 PMC: 11659764. DOI: 10.3389/fcell.2024.1514399.


Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy.

Erebor J, Agboluaje E, Perkins A, Krishnakumar M, Ngwuluka N Adv Pharm Bull. 2024; 14(3):558-573.

PMID: 39494247 PMC: 11530881. DOI: 10.34172/apb.2024.046.


Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective.

Milewska S, Sadowska A, Stefaniuk N, Misztalewska-Turkowicz I, Wilczewska A, Car H Int J Mol Sci. 2024; 25(11).

PMID: 38892406 PMC: 11172452. DOI: 10.3390/ijms25116219.


Microneedle combined with iontophoresis and electroporation for assisted transdermal delivery of goniothalamus macrophyllus for enhancement sonophotodynamic activated cancer therapy.

Abd El-Kaream S, Hussein N, El-Kholey S, Elhelbawy A Sci Rep. 2024; 14(1):7962.

PMID: 38575628 PMC: 10994924. DOI: 10.1038/s41598-024-58033-7.


Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications.

Kciuk M, Alam M, Ali N, Rashid S, Glowacka P, Sundaraj R Molecules. 2023; 28(13).

PMID: 37446908 PMC: 10343677. DOI: 10.3390/molecules28135246.


References
1.
Mehta R, Yamada T, Taylor B, Christov K, King M, Majumdar D . A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis. 2011; 14(3):355-69. DOI: 10.1007/s10456-011-9220-6. View

2.
Perez-Herrero E, Fernandez-Medarde A . Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015; 93:52-79. DOI: 10.1016/j.ejpb.2015.03.018. View

3.
Liu Z, Delavan B, Roberts R, Tong W . Lessons Learned from Two Decades of Anticancer Drugs. Trends Pharmacol Sci. 2017; 38(10):852-872. DOI: 10.1016/j.tips.2017.06.005. View

4.
El-Andaloussi S, Jarver P, Johansson H, Langel U . Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J. 2007; 407(2):285-92. PMC: 2049024. DOI: 10.1042/BJ20070507. View

5.
Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta D . Paclitaxel: What has been done and the challenges remain ahead. Int J Pharm. 2017; 526(1-2):474-495. DOI: 10.1016/j.ijpharm.2017.05.016. View